Ventilatory responses to hypoxia in rats pretreated with nonpeptide NK1 receptor antagonist CP-96,345.
This study reports experiments designed to evaluate the role of neurokinin-1 (NK1) receptors for substance P (SP) in the ventilatory response to acute hypoxia. Ventilation was measured by indirect plethysmography in eight unanesthetized unrestrained adult rats before and after bolus injection of 1, 5, or 10 mg/kg (ip) of CP-96,345 (Pfizer), a potent nonpeptide competitive antagonist of the SP NK1 receptor. Ventilation was measured while the rats breathed air or 8% O2-92% N2 with and without administration of SP antagonist. Pretreatment with CP-96,345 decreased the magnitude of the hypoxic response in a dose-dependent fashion. Minute ventilation in rats pretreated with CP-96,345 was reduced by 22.1% (P < 0.05) at the highest dose (10 mg/kg), largely because of an attenuation of the frequency component. Although both control and treated rats responded to hypoxia with a decrease in duration of inspiration and expiration rats pretreated with CP-96,345 displayed a smaller decrease in inspiration and expiration than control rats (P < 0.05). We have recently shown that neuropeptide-containing fibers are important for mediating the tachypnic response during acute isocapnic hypoxia in rats. The attenuation in minute ventilation at the highest dose (10 mg/kg) is comparable in magnitude to the attenuation observed with neonatal capsaicin treatment, which permanently ablates neuropeptide-containing unmyelinated fibers. Accordingly, this previously reported role of capsaicin-sensitive nerves in the hypoxic ventilatory response of rats is probably attributable to released SP acting at NK1 receptors. One of the likely sites of action of SP antagonists is the carotid body.(ABSTRACT TRUNCATED AT 250 WORDS)
De Sanctis
G T
GT
Department of Internal Medicine, University of Calgary, Alberta, Canada.
Green
F H
FH
Jiang
X
X
King
M
M
Remmers
J E
JE
D000818:Animals; D000831:Animals, Newborn / Q000502:physiology; D001713:Biphenyl Compounds / Q000494:pharmacology*; D002211:Capsaicin / Q000494:pharmacology; D005260:Female; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D000860:Hypoxia / Q000503:physiopathology*; D066298:In Vitro Techniques; D009412:Nerve Fibers / Q000187:drug effects / Q000502:physiology; D064729:Neurokinin-1 Receptor Antagonists; D010991:Plethysmography; D051381:Rats; D011916:Rats, Inbred F344; D012129:Respiratory Function Tests; D015656:Respiratory Mechanics / Q000502:physiology*; D013373:Substance P / Q000037:antagonists & inhibitors / Q000502:physiology; D013990:Tidal Volume / Q000502:physiology
D001713:Biphenyl Compounds; D006993:Hypnotics and Sedatives; D064729:Neurokinin-1 Receptor Antagonists; D013373:Substance P; D002211:Capsaicin; C066892:CP 96345